Modern approach to the treatment of atopic dermatitis with preserved fetal liver cells (experimental study)

Abstract

One of the urgent problems of modern dermatology is atopic dermatitis (AD), which has multifactorial pathogenesis, the significant prevalence of the disease, the increased frequency of the complicated course, the lack of radical methods of therapy. The expediency to use cryopreserved fetal liver cells (cFLCs) for the treatment of AD is proved by a wide range of produced by them biologically active substances with immunomodulatory and anti-inflammatory activity. Disclosure of the mechanisms of the therapeutic action of biotherapeutic drugs in AD provides for the determination of the state of the cellular and humoral links of the immune system (IS). In this regard, the aim of the work was to assess the effectiveness of cFLCs injection by characteristic clinical and immunological parameters in rats with AD. The results of the study in rats with AD revealed disorders in the IS, manifested in a decrease in the total number of T-lymphocytes and their subpopulations in the spleen, in an increase in the level of circulating immune complexes and a number of immunoglobulins in the blood serum, and in a decrease in the phagocytic activity of the peritoneal cavity cells. Therapy with cFLCs, in contrast to the standard treatment with prednisolone, significantly improves the therapeutic effect, which is demonstrated by the restoration of the parameters of the cellular and humoral links of the immune system in animals with AD. The amplifying effect of the combined use of cFLCs and prednisolone on a number of parameters of the immune system in AD was shown.